<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109013</url>
  </required_header>
  <id_info>
    <org_study_id>2158-61-07-21-06</org_study_id>
    <nct_id>NCT05109013</nct_id>
  </id_info>
  <brief_title>Juvenile Essential Arterial Hypertension and Vascular Function</brief_title>
  <official_title>Juvenile Essential Arterial Hypertension and Vascular Reactivity in Systemic and Cerebral Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Josip Juraj Strossmayer University of Osijek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Josip Juraj Strossmayer University of Osijek</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to investigate the association of the juvenile essential&#xD;
      arterial hypertension with systemic micro- and macrovascular reactivity and cerebral vascular&#xD;
      function, and to examine the potential impact of elevated oxidative stress on this&#xD;
      associations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic microvascular function in children</measure>
    <time_frame>Day 1.</time_frame>
    <description>Skin microvascular reactivity assessed by Laser Doppler flowmetry (post-occlusive reactive hyperemia, iontophoresis of acetylcholine and sodium nitroprusside) - measured in perfusion units (PU)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic macrovascular function in children</measure>
    <time_frame>Day 1.</time_frame>
    <description>Vascular ultrasound measurement of brachial artery response to vascular occlusion (flow mediated dilation; FMD, %)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerabral vascular function in children</measure>
    <time_frame>Day 1.</time_frame>
    <description>Cerebral blood flow velocities assessed by transcranial Doppler sonography (cm/s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress - thiobarbituric acid reactive substances (TBARS)</measure>
    <time_frame>Day 1.</time_frame>
    <description>Serum sample collection for measurement of biomarkers of oxidative stress level. Thiobarbituric acid reactive substances (TBARS) - biomarker of lipid peroxidation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocan</measure>
    <time_frame>Day 1.</time_frame>
    <description>Serum sample collection for ELISA measurement of serum endocan level - proteoglycan associated with endothelium activation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Day 1.</time_frame>
    <description>Automatic oscillometric measurement of blood pressure (in mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>Day 1.</time_frame>
    <description>Automatic oscillometric measurement of heart rate (bpm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>Day 1.</time_frame>
    <description>Measurement of body weight (kg) and body height (cm) from which will be combined to report body mass index (BMI) using formula: weight (kg) / [height (m)]2 (kg/m2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition - Fat Free Mass estimation</measure>
    <time_frame>Day 1.</time_frame>
    <description>Body composition status measured by a fourterminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically dervide formulas (the original manufacturer's software) will be used to calculate the estimated Fat Free Mass (FFM kg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition - Fat estimation</measure>
    <time_frame>Day 1.</time_frame>
    <description>Body composition status measured by a fourterminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically dervide formulas (the original manufacturer's software) will be used to calculate the estimated Fat (Fat Mass kg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body fluid status</measure>
    <time_frame>Day 1.</time_frame>
    <description>Body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Total Body Water (TBW L), Extracellular Water (ECW L), Intracellular Water (ICW L), Plasma Fluid (PF L) and Interstitial Fluid (IF L).</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Child, Only</condition>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>NT group - normotensive children</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HT group - hypertensive children</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        children aged 9-18 years of both sexes; normotensive and children with essential arterial&#xD;
        hypertension&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy normotensive children and children with essential arterial hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary arterial hypertension&#xD;
&#xD;
          -  other systemic diseases with immunopathology&#xD;
&#xD;
          -  neurodegenerative diseasesat&#xD;
&#xD;
          -  children that use therapy which has a high impact on vascular or immunological&#xD;
             function (immunotherapy, immunosuppressive therapy, sistemic corticosteroid therapy&#xD;
             etc..).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Kos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osijek University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Kos, MD</last_name>
    <phone>+385981748381</phone>
    <email>mkatic983@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osijek University Hospital</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Kos, MD</last_name>
      <phone>+385981748381</phone>
      <email>mkatic983@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Josip Juraj Strossmayer University of Osijek</investigator_affiliation>
    <investigator_full_name>Ines Drenjancevic</investigator_full_name>
    <investigator_title>Head of Department of Physiology and Immunology Faculty of Medicine Osijek</investigator_title>
  </responsible_party>
  <keyword>cerebral circulation</keyword>
  <keyword>child</keyword>
  <keyword>endothelium</keyword>
  <keyword>microcirculation</keyword>
  <keyword>macrocirculation</keyword>
  <keyword>hypertension</keyword>
  <keyword>oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

